nach oben

Erschienen in:

Open Access 30.09.2020 | Original Article

REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal

verfasst von: S. Batista, C. C. Nunes, J. J. Cerqueira, Ana Martins Silva, J. Correia de Sá, J. Ferreira, M. T. Mendonça, J. Pinheiro, V. Salgado, A. S. Correia, J. Sequeira, A. Costa, L. Sousa

Erschienen in: Neurological Sciences | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS).

Objectives

To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal.

Methods

Retrospective, multicentre, non-interventional study, reporting 3 years follow-up of data collected from October 2015 to July 2016. Sociodemographic data and previous treatments at baseline and data regarding disease evolution, including number of relapses, annualised relapse rates (ARR) and Expanded Disability Status Scale (EDSS), were collected.

Results

Two-hundred and seventy-five participants were enrolled in the REALMS study. Results showed that the main reason to switch to fingolimod was failure of previous treatment (56.7%) and only 3.6% were naïve patients. In the total population, there was a significant decrease in ARR of 64.6% in the first year of treatment, 79.7% in the second year and 82.3% in the third year, compared with baseline. More than 67.0% of patients had no relapses during the 3 years after switching to fingolimod. EDSS remained stable throughout the study.

Conclusions

Therapy with fingolimod showed a sustained effectiveness and safety over the 3 years, particularly on patients switched from first-line drugs (BRACE). No new safety issues were reported.

La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 4:CD009371PubMed

AlSharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, Inshasi J, Kurtuncu M, Müller T, Retief C, Sahraian MA, Shaygannejad V, Slassi I, Taha K, Zakaria M, Sørensen PS (2020) Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A Narrative Review. Neurol Ther

Chun J, Hartung HP (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33:91–101CrossRef

Dalla Costa G, Finardi A, Garzetti L, Carandini T, Comi G, Martinelli V, Furlan R (2018) Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients. Neurol Sci 39:373–376CrossRef

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401CrossRef

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415CrossRef

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556CrossRef

Fingolimod SPC. Approved by EMA. Updated 2017

Direcção Geral de Saúde Portugal (2015) Norma de Orientação Clínica sobre Terapêutica Modificadora da Esclerose Múltipla em Idade Pediátrica e no Adulto

10.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J (2018) Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med 379:1017–1027CrossRef

11.

Correia I, Batista S, Marques IB, Sousa M, Ferreira R, Nunes C, Macario MC, Sousa L (2016) The effectiveness of fingolimod in a Portuguese real-world population. Mult Scler Relat Disord 6:41–48CrossRef

12.

Izquierdo G, Damas F, Paramo MD, Ruiz-Pena JL, Navarro G (2017) The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study. PLoS One 12:e0176174CrossRef

13.

Mazibrada G, Sharples C, Perfect I (2018) Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK. Mult Scler J Exp Transl Clin 4:2055217318801638PubMedPubMedCentral

14.

Zecca C, Roth S, Findling O, Perriard G, Bachmann V, Pless ML, Baumann A, Kamm CP, Lalive PH, Czaplinski A (2018) Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis. Eur J Neurol 25:762–767CrossRef

15.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL (2017) Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurol Sci 38:53–59CrossRef

16.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRef

17.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444–1452CrossRef

18.

Ribeiro de Barros AH, Fiadeiro Sequeira JP, Lopes de Sousa AS, Chegancas Capela CM, Gomes Pedrosa RM, Dos Santos Manita MA (2018) Safety and Effectiveness of Fingolimod in Real-World Multiple Sclerosis Portuguese Patients. Clin Neuropharmacol 41:129–135CrossRef

19.

Ticha V, Kodym R, Pocikova Z, Kadlecova P (2017) Real-World outcomes in fingolimod-treated patients with multiple sclerosis in the Czech Republic: results from the 12-month GOLEMS study. Clin Drug Investig 37:175–186CrossRef

20.

Mallada-Frechin J, Meca-Lallana V, Barrero F, Martinez-Gines ML, Marzo-Sola ME, Ricart J, Garcia E En Representacion de Los Investigadores Del Estudio Ms Next E (2018) [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study]. Rev Neurol 67:157–167

21.

Comi G, Pozzilli C, Morra VB, Bertolotto A, Sangalli F, Prosperini L, Carotenuto A, Iaffaldano P, Capobianco M, Colombo D, Nica M, Rizzoli S, Trojano M (2020) Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurol Sci

22.

Ziemssen T, Albrecht H, Haas J, Klotz L, Lang M, Lassek C, Schmidt S, Tackenberg B, Cornelissen C (2017) 5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany. Poster P6345 presented at the 69th American Academy of Neurology (AAN) annual meeting, April 22 – 28, 2017, Boston

23.

Ziemssen T, Kern R, Cornelissen C (2015) The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol 15:93CrossRef

24.

Ziemssen T, Albrecht H, Haas J, Klotz L, Lang M, Lassek C, Schmidt S, Tackenberg B, Cornelissen C (2016) 4 years PANGAEA: long term data on effectiveness and safety from natalizumab patients switching to fingolimod in real world. Poster P6188 presented at the 68th American Academy of Neurology (AAN) annual meeting, April 15 – 21, 2016, Vancouver

25.

Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R (2014) Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait. CNS Drugs 28:817–824CrossRef

26.

Ouspid E, Razazian N, Moghadasi AN, Moradian N, Afshari D, Bostani A, Sariaslani P, Ansarian A (2018) Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran. Neurosciences (Riyadh) 23:129–134CrossRef

27.

Ziemssen T, Albrecht H, Haas J, Klotz L, Lang M, Lassek C, Schmidt S, Tackenberg B, Cornelissen C (2016) 4 years PANGAEA: A 5-year non-interventional study of safety, effectiveness and pharmacoeconomic data for fingolimod patients in daily clinical practice – effectiveness update. Poster P3072 presented at the 68th American Academy of Neurology (AAN) annual meeting, April 15 – 21, 2016, Vancouver

28.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G (2015) Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 84:1582–1591CrossRef

29.

Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85:653–666CrossRef

30.

Ziemssen T, Albrecht H, Haas J, Klotz L, Lang M, Lassek C, Schmidt S, Tackenberg B, Cornelissen C (2017) 5 years safety of fingolimod in real world: First results from PANGAEA, a noninterventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice. Poster P5365 presented at the 69th American Academy of Neurology (AAN) annual meeting, April 22 – 28, 2017, Boston

31.

Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM (2006) Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 63:1686–1691CrossRef

Titel: REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
verfasst von: S. Batista
C. C. Nunes
J. J. Cerqueira
Ana Martins Silva
J. Correia de Sá
J. Ferreira
M. T. Mendonça
J. Pinheiro
V. Salgado
A. S. Correia
J. Sequeira
A. Costa
L. Sousa
Publikationsdatum: 30.09.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 5/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04726-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal